The overarching goal of our laboratory is to understand the biology of normal haematopoietic and leukaemic stem cells in order to selectively kill cancer stem cells for better leukaemia treatment.
RNA Binding Protein Syncrip Is Required for the Low-Output HSC By Sustaining Proteome Quality. Blood (2021) 138 (Supplement 1): 296. https://doi.org/10.1182/blood-2021-147575
Transcriptional control of CBX5 by the RNA binding proteins RBMX and RBMXL1 maintains chromatin state in myeloid leukemia. Nat Cancer (2021) 2:741-757. PMID: 34458856
N 6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer Cell (2021) 39(7):958-972.e8. PMID: 34048709
HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells. Nat Commun (2020) 11(1):2026. PMID: 32332729
Stem cells are key to our normal development. When a stem cell divides into two, it creates one progenitor and one renews itself. The progenitor continues differentiating into mature specialised cells while the stem cell repeats the division cycle of making progenitors and reproducing themselves. Stem cells survive much longer than ordinary cells, increasing the chance of accumulating mutations. It might take only a few mutations for one cell to lose control over its self-renewal, divide uncontrollably and become the source of cancer.
Cancer stem cells (CSCs) are a small population of rare cells that can self-renew and differentiate into cancerous cells that proliferate uncontrollably, supplying the tumor mass. Conventional therapies, such as chemo- or radiotherapy, often target proliferating cells, leaving CSCs untouched. Therefore, CSCs are the underlying source of drug resistance and disease relapse.
The overarching goal of our laboratory is to understand the biology of normal haematopoietic (HSCs) and leukaemic stem cells (LSCs) in order to selectively kill cancer stem cells for better leukaemia treatment.
Gene expression defines the fate and function of each cell. Our recent work and others have demonstrated that post-transcriptional regulation of gene expression by RNA-binding proteins (RBPs) plays a critical role in cancer including leukaemia (Vu,…, Nguyen et al. 2017; Nguyen et al. Nat. Comms 2020; Cheng,…, Nguyen et al. Cancer Cells 2021; Prieto and Nguyen et al. Nat Cancer 2021). Importantly, the identification of dysregulated RBPs in leukaemia has led to the rapid development of therapeutic strategies to specifically target several RBPs. Despite their importance and therapeutic potential, only a small fraction of RNA regulators (>1,700 known RBPs) has been investigated in leukaemia.
Our lab aims to expand understanding of how dysregulated post-transcriptional processes contribute to the initiation and progression of various types of leukaemia. We particularly focus on acute myeloid leukaemia (AML) which has been one of the most aggressive and fatal types of blood cancer. To achieve this aim, we will:
We will address this question using state-of-the-art tools including unbiased omic approaches to map RBPs’ binding sites and activities including HyperTRIBE (Nguyen et al., Nat Comms, 2020), Ribo-STAMP (Brannan et al. Nat Methods 2021) and high-end Mass spectrometry, combined with molecular biology techniques, on animal models, human primary samples and xenografts.
The ultimate goal of our research is to determine the potential targetable RBPs and their molecular mechanisms of action. Once validated, these targets can be used for designing innovative drugs that selectively eradicate LSCs in AML, while sparing normal HSCs.
I received my undergraduate degree in Biology from Hanoi University of Science, before obtaining my MSc in Biomolecular Sciences from Vrije Universiteit Amsterdam and the Whitehead Institute for Biomedical Research, MIT, under support from Huygens Scholarship. I was awarded an EC Marie Curie Fellowship to complete my PhD (DPhil) from the University of Oxford, UK. My PhD work focused on the role of chromatin remodeling factor ATRX in congenital genetic disorders and cancers. I uncovered the genomic regions ATRX interacts with and how ATRX loss leads to genome instability.
After completing my PhD, I moved to the Memorial Sloan-Kettering Cancer Center in New York, USA for my postdoctoral training in Dr. Michael Kharas’ laboratory, investigating the role of post-transcriptional regulation in normal and malignant cancer stem cells. I pioneered the use of RNA-editing based approaches to identify RNA targets of RNA-Binding Proteins (RBPs) in mammalian stem cells, which has provided new insights into RBP function in rare cells and opened a new avenue for stem cell research. I also discovered the oncogenic role of a number of RBPs in blood cancer.
I am a recipient of the American Society of Hematology (ASH) Scholar Fellowship that supports my transition to independence. In August 2020, I was awarded the prestigious Career Development Fellowship from Cancer Research UK to start her my group at the Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London.